Suzy E Meijer, Ora Halutz, Amos Adler, Katya Levytskyi, Luba Tau, Michal Dekel, Ronit Cohen-Poradosu, Evgene Katchman, David Shasha, Jacob Ablin, Guy Choshen, Giris Jacob, Asaf Wasserman, Merav Ingbir, Yael C Cohen, Chava Perry, Ron Ram, Yair Herishanu, Yael Bar On, Elma van Thijn, Natalie Rutsinsky, Sheri Harari, Adi Stern, Ronen Ben-Ami, Yael Paran
In hemato-oncological patients, COVID-19 can present as a persistent infection with ongoing symptoms and viral replication over a prolonged period of time. Data are scarce on the preferred treatment options for these patients. We describe our experience with a five-day course of dual anti-viral treatment with remdesivir and nirmatrelvir/ritonavir for hemato-oncological immunocompromised patients with persistent COVID-19. Fifteen patients with a history of lymphoma, CLL, and MM were included. Eight were male, median age was 74...
November 7, 2023: Journal of Infection and Chemotherapy: Official Journal of the Japan Society of Chemotherapy